- Home
- RXST vs RIGL Comparison
RXST vs RIGL Comparison
Compare RXST & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- RIGL
- Stock Information
- Founded
- RXST 1997
- RIGL 1996
- Country
- RXST United States
- RIGL United States
- Employees
- RXST N/A
- RIGL N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RXST Health Care
- RIGL Health Care
- Exchange
- RXST Nasdaq
- RIGL Nasdaq
- Market Cap
- RXST 385.0M
- RIGL 335.5M
- IPO Year
- RXST 2021
- RIGL 2000
- Fundamental
- Price
- RXST $8.35
- RIGL $29.08
- Analyst Decision
- RXST Hold
- RIGL Buy
- Analyst Count
- RXST 11
- RIGL 5
- Target Price
- RXST $11.80
- RIGL $38.20
- AVG Volume (30 Days)
- RXST 792.1K
- RIGL 668.8K
- Earning Date
- RXST 11-06-2025
- RIGL 11-06-2025
- Dividend Yield
- RXST N/A
- RIGL N/A
- EPS Growth
- RXST N/A
- RIGL N/A
- EPS
- RXST N/A
- RIGL 5.43
- Revenue
- RXST $147,059,000.00
- RIGL $267,921,000.00
- Revenue This Year
- RXST N/A
- RIGL $59.93
- Revenue Next Year
- RXST $6.71
- RIGL N/A
- P/E Ratio
- RXST N/A
- RIGL $5.32
- Revenue Growth
- RXST 27.68
- RIGL 105.62
- 52 Week Low
- RXST $6.32
- RIGL $13.57
- 52 Week High
- RXST $55.57
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- RXST 42.47
- RIGL 34.14
- Support Level
- RXST $8.55
- RIGL $27.75
- Resistance Level
- RXST $9.39
- RIGL $29.46
- Average True Range (ATR)
- RXST 0.48
- RIGL 1.52
- MACD
- RXST -0.10
- RIGL -0.64
- Stochastic Oscillator
- RXST 1.40
- RIGL 13.86
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.